Skip to main content
Premium Trial:

Request an Annual Quote

Short-Term Incentive

Citing Forbes contributor Jim Golden's take on genomics in clinical oncology, Mike the Mad Biologist says microbial genomics will become more profitable than human genomics over the short term. "Microbial genomes are cheap, fast, and you can provide epidemiological relevant information to clinical laboratories, hospital networks, and public health departments," Mike says, later adding, "in two or three years, I don't see any technical hurdles to routine microbiological surveillance in hospitals." By comparison, human genomes are costly, take considerably longer, and do not necessarily yield clinically actionable information, Mike notes.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.